PA MedTech VC Fund

The fund sources exclusively from Shifamed, the Silicon Valley-based medical device incubator founded by Amr Salahieh. PA MedTech has a dedicated relationship with Shifamed that provides its limited partners access to the incubator's portfolio companies, which are typically not available through open venture fundraises. This single-pipeline model concentrates sourcing risk but removes the challenge of competing for allocation in broadly syndicated MedTech rounds.

PA MedTech functions as a dedicated capital access vehicle for Shifamed's portfolio. Shifamed itself is not the fund manager — Picard Angst runs PA MedTech independently from Switzerland — but the fund's investment universe is limited to companies that emerge from Shifamed's internal incubation process. Shifamed portfolio companies include Caisson Interventional (transcatheter mitral valve replacement) and Supira Medical (percutaneous ventricular assist), both of which PA MedTech has backed.

The fund concentrates on cardiovascular devices, which form the majority of the Shifamed pipeline given the incubator's structural heart origins. A secondary emphasis covers ophthalmology devices. Within cardiovascular, the portfolio spans structural heart, electrophysiology, and mechanical circulatory support. The fund invests from Series A through late-clinical stages, typically entering after initial proof-of-concept data and remaining through FDA pivotal trials.

PA MedTech itself does not typically take board seats, as Shifamed provides operational leadership and board representation for its incubated companies. The fund's role is capital provision with portfolio monitoring conducted through regular reporting channels maintained by Shifamed. Picard Angst and the fund's investment committee review clinical and regulatory milestones but do not insert operational personnel into the companies.

The investor base consists primarily of Swiss and European high-net-worth individuals and family offices, with select institutional participation. The fund's Pfäffikon domicile reflects its Swiss private-banking distribution channel and the geographic concentration of its limited partner relationships, though specific LP names are not publicly disclosed.

Shifamed's incubation model typically targets exits within five to eight years of initial company formation, with sale to strategic acquirers as the primary exit path. Medtronic has been a past acquirer of Shifamed portfolio companies, providing a template for the fund's return expectations. PA MedTech does not maintain a separate secondary process — exits flow through the Shifamed company's board-level M&A or IPO decisions.

The fund's exclusive sourcing arrangement with Shifamed means portfolio concentration is high — typically five to ten positions per vintage — and all exposure is to a single incubator's pipeline. This creates correlation risk if Shifamed's device designs encounter clinical setbacks or regulatory delays. The fund does not diversify across MedTech incubators or pursue generalist venture exposure, making it unsuitable as a standalone MedTech allocation but potentially viable as a complementary sleeve for investors who already hold diversified healthcare venture positions.